Lynparza (olaparib)

pCPA File Number: 22319

Negotiation Status:

Concluded with an LOI

Indication(s):

Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer, for adjuvant treatment of adult patients who have been treated with neoadjuvant or adjuvant chemotherapy

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0299-000

pCPA Engagement Letter Issued:

2023-04-19

Negotiation Process Concluded:

2023-06-06